Posted by Michael Wonder on 17 Jun 2026
Inhibrx announces US FDA acceptance of BLA for ozekibart in patients with conventional chondrosarcoma
15 June 2026 - Inhibrx Biosciences today announced that the US FDA has accepted for filing its biologics license application seeking approval of ozekibart (INBRX-109) for the treatment of patients with unresectable or metastatic conventional chondrosarcoma.
The FDA has not identified any filing review issues at this time and has assigned a PDUFA goal date of 14 April 2027.
